Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

TRDA Entrada Therapeutics, Inc. Common Stock
$5.61 3.51% +0.19
Notify me if price changes either direction
Interactive Brokers Logotype

Buy TRDA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 218.4M
Enterprise value 23.1M
Trailing PE 10.051724
Forward PE -1.820598
PEG Ratio -3.4845976533333
Enterprise to EBITDA -0.135
Enterprise to revenue 4.936
Price to book MRQ 0.84659356
Price to sales TTM 45.534134

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 4.7M
EBITDA -170863008
Diluted EPS TTM -4.04
Total Cash (MRQ) 223.0M
Current ratio (MRQ) 10.889
Operating Cash Flow (TTM) -134674000

TRDA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent TRDA News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.